<ul><li>A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks.</li><li>The study enrolled 225 adults aged 18 to 50 years who had not previously been vaccinated against mpox or smallpox.</li><li>Participants receiving one-fifth of the standard dose had antibody levels equivalent to those receiving the standard regimen after two weeks.</li><li>Participants receiving one-tenth of the standard dose had lower antibody levels compared to the standard regimen at all measurements.</li></ul>

Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen

Discover more